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A B S T R A C T   
Background: Pediatric, adolescent, and young adult (PAYA) cancer survivors suffer from multiple domains of 
adverse psychosocial and behavioral outcomes during and after their cancer treatment. This study conducted a 
systematic review and metaanalysis of psychosocial, behavioral, and supportive interventions for PAYA cancer 
survivors. 
Methods: We searched 11 electronic databases, 4 professional websites, and manual search of reference lists in 
existing reviews. We selected randomized controlled trials and controlled trials without randomization focusing 
on PAYA cancer survivors across six outcome domains. 
Results: We included 61 studies (4,402 participants) published between 1987 and 2020. Overall risk of bias across 
studies was low. We identified an overall moderate and statistically significant treatment effect size for PAYA 
cancer survivors across six outcome domains. 
Conclusion: psychosocial, behavioral, and supportive interventions were overall effective for PAYA cancer sur-
vivors. However, interventions were not effective for certain outcome domains, and less effective among AYA 
versus pediatric cancer survivors.   
1. Introduction 
Pediatric, adolescent, and young adult cancer survivors (PAYA sur-
vivors) are individuals who have/had a cancer diagnosis between the 
ages 0–39 years old. In 2018, there were over 650,000 PAYA survivors in 
the United States (Close et al., 2019; Segal et al., 2018). Despite recent 
medical advances and significant improvements in 5-year cancer sur-
vival rates, most PAYA survivors experience adverse late, long-term, or 
persistent medical, behavioral, psychosocial, spiritual, and/or existen-
tial outcomes cause by cancer or cancer treatments (Shay et al., 2017; 
Marjerrison and Barr, 2018; Hydeman et al., 2019). PAYA survivors are 
more likely than older cancer survivors to suffer from 
bio-psycho-social-spiritual challenges as a result of their cancer 
experience, such as risky health behaviors, low self-esteem, increased 
mortality, and suicide risk (Penn et al., 2017; Zhou et al., 2019; Hara-
shima and Fujimori, 2020). Given their age, PAYA cancer survivors are 
arguably the most vulnerable cancer sub-population to adverse survi-
vorship outcomes (Lang et al., 2018). 
The known risks, complex needs, and challenging survivorship out-
comes for PAYA survivors highlight the importance of understanding the 
efficacy of evidence-informed psychosocial, behavioral, and supportive 
interventions that health care providers may integrate into their prac-
tice. We broadly define psychosocial, behavioral, and supportive in-
terventions as any type of interventions supporting PAYA cancer 
survivors that are not medical or pharmaceutical in nature (Page and 
Adler, 2008). These may include psycho-therapeutic interventions (like 
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motivational interviewing or behavioral activation), (psycho)educa-
tional programs (to increase PAYA survivors’ cancer-related knowl-
edge), and online peer support groups to increase PAYA survivors’ 
physical activities, among other forms of interventions. 
Although systematic reviews and meta-analyses on this topic exist, 
(Braam et al., 2016; Bukola and Paula, 2017; Mizrahi et al., 2017; Pai 
et al., 2006; Richter et al., 2015) gaps in this literature warrant an 
updated systematic review and synthesis of the interventions examined 
in those studies. First, all existing systematic reviews focused on narrow 
topics, e.g. cognitive-behavioral therapy for depressive symptoms only, 
and thus do not reflect the complex nature of survivors’ post-treatment 
experience and the heterogeneity of interventions for PAYA cancer 
survivors. It is important to be inclusive of all types of interventions for 
multiple domains of outcomes because oncology providers often need to 
make treatment recommendations for PAYA patients facing a multitude 
of bio-psycho-social-behavioral challenges. Drawing on several con-
ceptual and theoretical papers on survivorship care among PAYA sur-
vivors, (Shay et al., 2017; Marjerrison and Barr, 2018; Hydeman et al., 
2019; Baird et al., 2019; Lewis et al., 2014), authors of this review 
developed a 6-domain conceptual framework to guide the categoriza-
tion of survivorship outcomes: 1. (Physical) health domain, including 
physical symptoms and functional health, and health-related behaviors; 
2. Psychological domain, including mental health, cognitive health, and 
other types of psychological outcomes; 3. Social (relational) domain; 4. 
Academic domain; 5. General quality of life; and 6. Cancer related 
knowledge (see eAppendix for detail). 
Second, due to the narrow scope of many reviews (thus small number 
of included studies), most existing review studies were unable to 
perform meta-analysis to estimate an overall treatment effect. While still 
highly valuable, existing qualitative systematic reviews did not provide 
a statistical analysis on the treatment effect of different types of in-
terventions, which makes it challenging for oncology providers to 
engage in evidence-based practice. Finally, many existing reviews were 
completed before 2015 (5 years ago). Therefore, an update of the 
literature is also warranted. 
Given gaps in the existing literature, we conducted a systematic re-
view and meta-analysis of clinical trials evaluating psychosocial and 
behavioral interventions for PAYA cancer survivors. The goal is to 
provide an updated, yet comprehensive review of all psychosocial in-
terventions intended to have effects on the multiple and varied outcome 
domains of survivorship (defined above). Doing so will better inform 
survivorship care for this population, as it will provide a more nuanced 
and focused analyses to inform best practices for psychosocial oncology 
care providers. In this review, a cancer survivor is defined as any indi-
vidual since the moment of receiving a cancer diagnosis (Mayer et al., 
2017). Adapting such definition would enable this review including 
treatments supporting PAYA cancer survivors both during and after their 
cancer treatments. 
2. Methods 
The Methodological Expectations of Cochrane Intervention Reviews 
(MECIR) guided the conduct of this systematic review and meta- 
analysis, and findings are reported in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-analysis (PRISMA). 
Study team included experts in pediatric, medical, and psychosocial 
oncology, including investigators with extensive experience in system-
atic review and meta-analysis. This review was pre-registered at 
PROSPERO: CRD42020200987. 
2.1. Search methods 
The study searched for controlled clinical trials (with or without 
randomization) of psychosocial and behavioral interventions for PAYA 
cancer survivors. We included all eligible articles from inception 
through June 1st, 2020. We carried out an electronic search across 11 
databases, 4 professional websites, and a manual search of the reference 
lists from published reviews relating to our study (eSupplement1). Two 
of the authors (A.Z. and C.T.) independently screened all trials to 
determine eligibility first by titles and abstracts, then by full texts using 
the Cochrane recommended platform, Covidence. Disagreements were 
resolved first through consensus and further discussion with a third/ 
senior reviewer (B.Z.). 
2.2. Population, intervention, and outcome measures 
Controlled trials for cancer survivors who fit NCI’s definition for 
pediatric, adolescent and young adult (diagnosed between the ages of 
0–39 years) were eligible for inclusion. Any interventions that were 
solely medical or pharmaceutical were excluded from this review. The 
primary outcome meta-analyzed in this study was the survivorship 
outcome, operationalized by combining all bio-psycho-social-behavioral- 
spiritual outcome domains together to reflect the complex nature of 
PAYA cancer survivorship. A second level of analysis involved exami-
nation of intervention effects separately by pre-determined domains of 
the survivorship (defined earlier): 1. (physical) health outcomes; 2. 
psychological outcomes; 3. social outcomes; 4. academic outcomes; 5. 
general quality of life; and 6. cancer knowledge. We included studies 
published in English but posed no restriction for type of publication. 
2.3. Data extraction 
A data extraction sheet (eSupplement2) was developed by the study 
team including pediatric and adult clinicians as well as social and 
behavioral scientists in the psycho oncology realm. Two of us (A.Z. and 
C.T.) independently extracted the data from the included trials. In in-
stances of disagreement, a third reviewer was consulted (B.Z.). 
2.4. Risk of Bias assessment 
Risk of bias was assessed with the Cochrane Collaboration’s Risk of 
Bias tool 2nd version (RoB 2) (Sterne et al., 2019) for randomized 
controlled trial (RCT) and the Risk of Bias in Non-randomized Studies – 
of Interventions (ROBINS-I) tool (Sterne et al., 2016) for controlled trial 
study without randomization. The RoB 2 tool is the recommended tool 
to assess for RCTs included in Cochrane reviews. The RoB 2 tool eval-
uates 5 domains of bias focusing on different aspects of RCTs, and pro-
vides researchers a structured way scoring individual RCTs. The 5 
domains are: 1. Risk of bias arising from the randomization process; 2. 
Risk of bias due to deviations from the intended intervention; 3. (Risk of 
bias due to) Missing outcome data; 4. Risk of bias in measurement of the 
outcome; and 5. Risk of bias in selection of the reported result. The 
ROBINS-I tool is the Cochrane recommended tool to evaluate risk of bias 
for non-randomized studies of interventions. The ROBINS-I tool sys-
tematically evaluates 7 domains of bias including: 1. Bias due to con-
founding; 2. Bias in selection of participants into the study; 3. Bias in 
classification of interventions; 4. Bias due to deviations from intended 
interventions; 5. Bias due to missing data; 6. Bias in measurement of 
outcomes; and 7. Bias in selection of the reported result. 
2.5. Data synthesis and statistical analysis 
Analyses were performed with R Statistical Software (version 4.0.2) 
with the metafor and robumeta package, using robust variance estimation 
(RVE) in meta-regression (Hedges et al., 2010). All outcomes were 
continuous, and we calculated the between group small sample size 
corrected Hedges’ g effect size, noted as d in this study, for 
meta-analysis. The sampling error variance of each d was calculated 
using procedures recommended by Cooper and colleagues (Cooper et al., 
2019). 
Given the clustered nature of our data, i.e., including multiple effect 
sizes reported in a single study, we used meta-regression with RVE, 
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which allows meta-analyzing multiple treatment effect sizes from the 
same study without compromising the validity of statistical inference. 
Heterogeneity was assessed using τ2 to estimate the between-study 
variance in study-average effect sizes. Because meta-regression with 
RVE produces robust estimation of the variance component regardless of 
the model selection (i.e. fixed versus random effect models), all meta- 
analyses were conducted without specifying a variance modeling strat-
egy. We planned subgroup analyses for survivorship outcome based on 
important study, participant, and intervention characteristics, 
including: 1. study design (RCT versus controlled trial without 
randomization); 2. age of PAYA survivors (pediatric only, or AYA only, 
or both); 3. intervention modality (individual versus non-individual 
intervention); 4. treatment component (single component, like cogni-
tive behavioral therapy, versus multiple components, like behavioral 
activation plus peer support); and 5. treatment formality (in-person 
versus tele-health interventions). Moderator analyses were conducted 
for the survivorship outcome overall (across domains) and for specific 
domains of survivorship outcomes. Sensitivity analyses were conducted 
accounting for risk of bias and outliers to ensure findings were not 
significantly altered. Publication bias was evaluated through both visual 
examination of funnel plots and the Vevea and Woods sensitivity 
weighting models (Vevea and Woods, 2005). 
3. Results 
3.1. Literature search 
An initial search of literature identified 10,026 references from 
electronic database searches and 34 relevant systematic reviews and/or 
meta-analysis studies to search through reference lists (Fig. 1). Title and 
abstract screening resulted in 94 references for full text screening, which 
further retained 59 studies for data synthesis. A search through the 
reference list of 34 relevant systematic reviews and/or meta-analysis 
studies identified 2 additional eligible trials, resulting in a final sam-
ple size of 61 studies and 664 effect sizes for data synthesis. On average, 
each study reported 11 effect sizes, ranging from 1 to 38 effect sizes per 
study with a standard deviation of 8.47. It is important to re-iterate that 
meta-regression with RVE effectively accounts for the clustered nature 
of our data so that those studies with more effect sizes are not over-
weighted in the final meta-analytic results. 
3.2. Trial characteristics 
Fifty-three randomized controlled trials and eight controlled trials 
without randomization, published between 1987 and 2020, included a 
total of 4,402 PAYA cancer survivors. Mean age across studies was 15.38 
years old, ranging from 6.5–32.79 years. Less than half of all participants 
(46.59 %) were female. Forty-four trials reported an average of 54.16 % 
of the participants being White, which included 9 clinical trials exclu-
sively targeting non-White races. Most trials were conducted in North 
America, i.e. United States or Canada (n = 38), seven in Europe, six in 
Hong Kong, one in Taiwan, seven in middle East countries, and two were 
multi-nation trials. All but one were trials published in peer-reviewed 
academic journals. 
Fifty-eight of the 61 trials (95.08 %) focused on PAYA survivors with 
various cancer diagnosis, leaving three diagnosis-specific trials one 
focusing on child leukemia, one on acute lymphoblastic leukemia, and 
one on medulloblastoma. Thirty-six trials (59.02 %) focused on pediatric 
cancer survivors, sixteen trials focused on AYA cancer survivors, leaving 
9 trials focusing on both pediatric and AYA cancer survivors. Fifty-two 
trials (85.25 %) delivered individual-based interventions and nine tri-
als (14.75 %) administered group-based or family-based interventions. 
Thirty-nine trials (63.93 %) delivered interventions with multiple 
components, e.g., psychoeducation plus skill training, and twenty-two 
trials (36.07 %) delivered single component interventions, e.g., cogni-
tive behavioral therapy, digital story-telling, and cognitive remediation 
treatment. Twenty-three trials (37.70 %) evaluated psychoeducation 
and/or skill training interventions, twenty-one (34.43 %) evaluated 
psychotherapeutic interventions, and seventeen (27.87 %) trials 
involved supportive care interventions, e.g., distraction for chemo-
therapy distress or digital storytelling application to improve quality of 
life. Thirty-three trials delivered in person intervention and twenty-nine 
trials used technology-assisted intervention. Supplemental Table 1 
provides details of the 61 studies including detailed references. 
3.3. Risk of Bias and publication Bias 
Risk of bias assessment (Supplemental TaTable 2ble 2) revealed 
overall low risk of bias for randomized controlled trials as well as for 
controlled trials without randomization. Several randomized controlled 
trials reported moderate risk of bias due to randomization and missing 
Fig. 1. PRISMA Diagram.  
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outcome data, whereas most controlled trials reported moderate risk of 
bias due to missing outcome data. Funnel plot indicated low concern for 
publication bias (Fig. 2). 
3.4. Survivorship outcomes 
Sixty-one trials of 664 effect sizes across the six pre-determined do-
mains of survivorship outcome reported an overall statistically signifi-
cant treatment effect, d = 0.470, 95 % CI 0.360, 0.579, τ2 = 0.24. 
Subgroup analyses by study and intervention characteristics (Table 1) 
revealed that the treatment effect was statistically significant regardless 
of study design (RCT versus controlled trials without randomization), 
across targeted population (pediatric survivors only, or AYA survivor 
only, or PAYA survivors), treatment modalities (individual or non- 
individual based intervention), treatment components (single or multi-
ple components), and delivery format (in person delivery or telehealth 
involved). 
Univariate moderator analyses revealed that age and targeted pop-
ulation were two significant moderators for survivorship outcomes 
(Table 2). Age significantly moderated the effect size of survivorship 
outcomes, b=-0.019, 95 % CI -0.031, -0.007. For each one-year increase 
in a study participants’ average age, that study is expected to report 
0.019 decrease in effect size. Studies targeting AYA survivors on average 
reported significantly smaller treatment effect than studies targeting 
PAYA survivors and pediatric survivors, b=-0.307, 95 % CI -0.545, 
-0.068 and b=-0.329, 95 % CI -0.533, -0.124, respectively. Outcome 
domain did not significantly moderate survivorship outcomes, meaning 
the difference of treatment effect between domains of survivorship 
outcomes did not significantly differ from zero. 
3.5. Domains of survivorship outcomes 
3.5.1. (Physical) health outcomes 
Subgroup analyses and within subgroup moderator analyses across 
outcome domains were presented in Table 3 and Table 4. Thirty-eight 
Fig. 2. Funnel Plot.  
Table 1 
Overall treatment effect and subgroup analysis results by study and intervention 
characteristics*.   
Estimate df N/K 95 % CI p value 






Study Design**       






- CT without 
randomization 




Targeted Population***       
















Treatment Modality       










Treatment Component       












Formality       












* df = degrees of freedom, it should be noted that for any effect size with a df <
4, a more conservative use of the p value should be adopted, i.e., p < 0.01 to be 
considered statistically significant. N/K for which N stands for the number of 
study and K stands for the number of effect size estimates. 
** RCT = randomized controlled trial; CT without randomization = controlled 
trial without randomization. 
*** AYA = adolescent and young adult. 
Table 2 
Univariate moderator analysis for survivorship outcomes*.   
Coefficient df N/K 95 % CI p value 






AYA versus PAYA 
** 














* All subgroup variables were tested as moderators and only significant results 
were presented. 
** An overall treatment effect for AYA survivors only when compared with an 
overall treatment effect for both pediatric and AYA survivors. 
*** An overall treatment effect for AYA survivors only when compared with an 
overall treatment effect for pediatric survivors only. 
Table 3 
Subgroup analysis results by domains of outcomes*.   
Estimate df N/K 95 % CI p value 
























































Cancer knowledge related 
outcomes 










* df = degrees of freedom, it should be noted that for any effect size with a df <
4, a more conservative use of the p value should be adopted, i.e., p < 0.01 to be 
considered statistically significant. N/K for which N stands for the number of 
study and K stands for the number of effect size estimates. 
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studies including 276 effect sizes reported an overall statistically sig-
nificant treatment effect, d = 0.424, 95 % CI 0.260, 0.589, τ2 = 0.33. 
Physical health outcomes were further categorized into 1. physical 
symptom outcomes and 2. health behavior outcomes. Physical symptom 
outcomes (31 studies and 178 effect sizes) reported an average treat-
ment effect d = 0.470, 95 % CI 0.291, 0.649, τ2 = 0.26. Health behavior 
outcomes (19 studies and 98 effect sizes) reported an average treatment 
effect d = 0.421, 95 % CI 0.141, 0.700, τ2 = 0.39. 
Age significantly moderated physical outcomes among PAYA cancer 
survivors, b=-0.018, 95 % CI -0.033, -0.003. For each one-year increase 
in a study participants’ average age, that study is expected to report 
0.018 decrease in effect size. No other study, participant, and interven-
tion characteristics were significant moderators for physical health 
outcomes. 
3.5.2. Psychological outcomes 
Thirty-nine studies including 262 effect sizes reported an overall 
statistically significant treatment effect, d = 0.528, 95 % CI 0.383, 
0.674, τ2 = 0.19. Psychological outcomes were further categorized into 
1. mental health outcomes, 2. cognitive wellness outcomes, and 3. 
general psychological wellness outcomes. Mental health outcomes (29 
studies and 99 effect sizes) reported an average treatment effect d =
0.582, 95 % CI, 0.407, 0.757, τ2 = 0.18. Cognitive wellness outcomes (6 
studies and 34 effect sizes) reported an average non-significant treatment 
effect d = 0.367, 95 % CI -0.192, 0.926, τ2 = 0.21. General psychological 
wellness (20 studies and 129 effect sizes) reported an average treatment 
effect d = 0.460, 95 % CI 0.183, 0.691, τ2 = 0.27. 
Moderator analyses revealed that age, intervention modality (indi-
vidual versus non-individual), and targeted population significantly 
moderated PAYA survivors’ psychological outcomes. For each one-year 
increase in a study participants’ average age, that study on average is 
expected to report a decrease in treatment effect of 0.026, b=-0.026, 95 
% CI, -0.042, -0.010. Non-individual interventions (e.g., family-based or 
peer-supported) reported significantly greater treatment effect than 
individual-based interventions, b = 0.324, 95 % CI 0.053, 0.595. Studies 
targeting AYA survivors reported an average of 0.332 lower treatment 
effect than studies targeting PAYA survivors, b=-0.332, 95 % CI -0.590, 
-0.073, as well as an average of 0.360 lower treatment effect than studies 
targeting pediatric survivors, b=-0.360, 95 % CI -0.659, -0.060. 
3.5.3. Social and academic outcomes 
Thirteen studies including 32 effect sizes of social outcomes reported 
an overall statistically significant treatment effect, d = 0.219, 95 % CI 
0.046, 0.359, τ2 = 0.05. Ten studies including 39 effect sizes of academic 
outcomes reported an overall statistically non-significant treatment ef-
fect, d = 0.257, 95 % CI, -0.001, 0.515, τ2 = 0.09. 
None of the study, participant, and intervention characteristics 
significantly moderated treatment effect size for social or academic 
outcomes. 
3.6. Cancer knowledge outcomes and general quality of life 
Six studies including 19 effect sizes of cancer knowledge outcomes 
reported an overall statistically non-significant treatment effect, d =
0.195, 95 % CI -0.152, 0.543, τ2 = 0.06. Seventeen studies including 36 
effect sizes of general quality of life reported an overall statistically 
significant treatment effect, d = 0.417, 95 % CI 0.193, 0.642, τ2 = 0.14. 
Age was the only significant moderator for quality of life outcomes, 
b=-0.133, 95 % CI, -2.40, -0.025. For each year increase in a study 
participants’ average age, a study is expected to report 0.133 lower 
treatment effect. 
4. Discussion 
This systematic review and meta-analysis evaluated psychosocial, 
behavioral, and supportive interventions for PAYA cancer survivors 
across multiple and varied survivorship outcome domains, and when 
delivered at various points in time throughout a continuum of cancer 
care. Overall, this study identified a moderate treatment effect for in-
terventions intended to affect survivorship outcomes, with the greatest 
treatment effect sizes observed among psychological and physical do-
mains, and general quality of life. More specifically, the two strongest 
treatment effects were observed among mental health outcomes and 
physical symptoms related to cancer treatment. Such findings were 
overall positive because compromised mental health and physical side 
effects are amongst the top cited short- and long-term adverse outcomes 
related to cancer treatment. 
Although statistically significant, existing interventions’ overall 
treatment effect for social (relational) outcomes was small. This is 
concerning because socialization is critical for achieving multiple 
milestones during the PAYA age range. Furthermore, the overall treat-
ment effects for academic and cancer knowledge outcomes were statis-
tically non-significant, highlighting the importance of more research 
into these domains. Most interventions targeting PAYA survivors’ aca-
demic or cancer knowledge outcomes were (psycho)educational pro-
grams that can be didactic and text heavy. As a result, PAYA cancer 
survivors may have low engagement with these interventions, resulting 
in low treatment effect. This highlights the importance of future 
research on developing and implementing engaging and interactive 
(psycho)educational programs to improve PAYA cancer survivors’ aca-
demic and cancer knowledge outcomes. 
A notable finding of this study is that treatment effects for survi-
vorship outcomes differ by age/developmental stages within the PAYA 
age range. In comparison to pediatric cancer survivors, treatment effects 
for multiple domains of survivorship outcomes were significantly lower 
among AYA cancer survivors. Despite recent national attention to sur-
vivorship needs of AYA cancer survivors, psychosocial interventions 
remain inadequate for this population, which calls for persistent clinical 
and research effort to improve care and survivorship outcomes for this 
unique population of cancer survivors. Cancer survivors who are ado-
lescents or emerging adults (15–26 years) receiving care at pediatric 
hospitals often find their age-specific needs are not sufficiently met 
(D’Agostino et al., 2011; Wong et al., 2017) given many pediatric hos-
pitals (and programs offered) are designed for young children. This 
could explain the treatment effect difference between pediatric versus 
Table 4 
Univariate moderator analysis for subdomains of outcomes*.   
Estimate df N/K 95 % CI p value 
Physical Outcomes      






Psychological Outcomes      


























Quality of Life 
Outcomes      






* All subgroup variables were tested as moderators and only significant results 
were presented. 
** An overall treatment effect for AYA survivors only when compared with an 
overall treatment effect for both pediatric and AYA survivors. 
*** An overall treatment effect for AYA survivors only when compared with an 
overall treatment effect for pediatric survivors only. 
A. Zhang et al.                                                                                                                                                                                                                                   
Critical Reviews in Oncology / Hematology 160 (2021) 103291
6
AYA cancer survivors. Another possible explanation could be the wide 
age spectrum of the AYA survivor population in comparison to pediatric 
cancer survivors. Most interventions for pediatric cancer survivors 
target individuals between 5–13 years old whereas AYA is defined be-
tween 15–39 years old. Although many researchers have agreed that this 
age range includes three distinct developmental stages (Barnett et al., 
2016; Zhang et al., 2020), i.e. adolescence (15–17), emerging adulthood 
(18–25), and young adulthood (26–39), many psychosocial research on 
AYA focused on all age stages to increase participants’ sample size and 
study feasibility. As a result, tested interventions may report lower 
treatment effect when compared with interventions developed targeting 
a smaller age range, e.g. young adult cancer survivors 18–25 years old. 
In-person and telehealth-involved psychosocial interventions for 
PAYA cancer survivors were equally effective. Although in-person in-
terventions reported greater treatment effect (d = 0.519) than 
telehealth-involved interventions (d = 0.397), the difference was not 
statistically significant. While encouraging, such finding does enunciate 
the significant needs of telehealth and tele-mental health research to 
improve survivorship outcomes for AYA cancer survivors, especially for 
the fact that AYA cancer survivors are a tech-prone and savvy 
generation. 
4.1. Findings in relation with current knowledge and existing reviews 
Our literature search identified 5 existing meta-analysis studies 
including one focusing on physical exercise training for PAYA cancer 
survivors’ outcomes (Braam et al., 2016) (n = 6); one focusing on psy-
chosocial intervention for AYA cancer survivors’ outcomes (Richter 
et al., 2015) (n = 7) and three focusing on pediatric cancer survivors 
(Bukola and Paula, 2017; Mizrahi et al., 2017; Pai et al., 2006). Our 
findings were consistent with existing reviews evaluating specific types 
of intervention for a subdomain of outcome, e.g., physical exercise for 
health outcomes among childhood cancer survivors (Mizrahi et al., 
2017). However, all existing reviews reported small treatment effects, 
which suggests limited clinical significance to these findings. To our 
knowledge, this review has a comprehensive and inclusive scope (n =
61, including 664 effect sizes and 4402 PAYA cancer survivors) evalu-
ating psychosocial interventions for PAYA survivors’ outcomes. We also 
provided subgroup and moderator analyses that allowed us to evaluate 
outcome domains that were not previously synthesized quantitatively, i. 
e., academic outcomes, and cancer knowledge, to provide better guid-
ance to the psychosocial care for PAYA survivors. 
4.2. Clinical implications 
Both pediatric and AYA cancer survivors are likely to benefit from 
psychosocial interventions for physical, psychological, social-relational 
outcomes and quality of life, but not for academic related outcomes or 
to improve their cancer knowledge. Recommendations for psychosocial 
interventions need to account for a patient’s age as the strongest effects 
were observed among studies for pediatric survivors. Especially for 
psychological outcomes, oncology providers need to be aware that 
existing research have reported significantly greater effect for pediatric 
cancer survivors than their AYA counterparts. 
4.3. Strengths and limitations 
This review was conducted and reported following established 
methodological guidelines. We used an a priori defined protocol and 
carried out an extensive literature search including both scientific and 
gray literature. Our focus on survivorship as a higher order construct is 
inclusive of common bio-psycho-social-spiritual challenges faced by 
PAYA cancer survivors. We used advanced statistical methods to over-
come known challenges of meta-analysis, i.e., including multiple mea-
sures of the same construct from the same study, to optimize statistical 
power. Similarly, the large sample size of included clinical trials and 
effect sizes alongside an overall strong quality rating of included studies 
provide us confidence in interpreting study findings. 
This review was limited by the available data, which were sometimes 
insufficient to conduct more complex analysis, i.e., multiple moderator 
analysis in meta-regression. Besides, many studies included in this re-
view did not clearly distinguish interventions for delivery during 
treatment from those intended to post-treatment survivors, which pre-
vented us from statistically comparing interventions at different care 
timepoints. In addition, there is always a chance that we did not include 
all available trials, though it is unlikely to impact our overall findings. 
Finally, due to limited space, we did not report further subgroup and 
moderator analysis within each domains of outcomes, which should be 
further disseminated in future publications. 
4.4. Conclusion 
In this systematic review and meta-analysis of psychosocial inter-
vention for PAYA cancer survivors’ survivorship outcomes, we identi-
fied an overall moderate statistically significant treatment effect. We 
found existing psycho-oncology interventions effective for physical, 
psychological, social, and quality of life outcomes but not for academic 
outcomes and cancer related knowledge. We are fairly confident with 
our findings given the scope of this review and the quality of included 
studies in general. Additional analyses focusing on subdomains of out-
comes should be reported in subsequent publications. 
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